Spyre Therapeutics (SYRE) Other Non-Current Assets (2015 - 2025)

Spyre Therapeutics has reported Other Non-Current Assets for 11 years, with the latest figure at $10000.0 in Q1 2025.

• For the quarter ending Q1 2025, Other Non-Current Assets changed 0.0% year-over-year to $10000.0; the trailing twelve-month figure through Mar 2025 stood at $10000.0 (changed 0.0% YoY), and the FY2024 full-year result was $10000.0, down 96.89% from the prior year.
• Other Non-Current Assets for Q1 2025 stood at $10000.0, roughly flat from $10000.0 in the prior quarter.
• The five-year high for Other Non-Current Assets was $1.8 million in Q2 2021, with the low at $10000.0 in Q1 2024.
• Historically, Other Non-Current Assets has averaged $1.0 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2021 — Other Non-Current Assets surged 1906.52% — and 2024, when it slumped 99.24%.
• Spyre Therapeutics' Other Non-Current Assets stood at $1.8 million in 2021, then declined by 15.51% to $1.6 million in 2022, then tumbled by 79.27% to $322000.0 in 2023, then slumped by 96.89% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
• The last three Other Non-Current Assets figures came in at $10000.0 (Q1 2025), $10000.0 (Q4 2024), and $10000.0 (Q2 2024), per Business Quant data.